BioCentury
ARTICLE | Clinical News

V7: Phase II started

August 15, 2011 7:00 AM UTC

Immune Network said its Immunitor Inc. business began the double-blind, Ukrainian Phase II imm02 trial to evaluate once-daily oral V7 plus standard of care (SOC) vs. placebo plus SOC in about 40 TB p...